Clarity from complexity. Eventually.
The same story won’t work for everyone. Multiple audiences with different depths of knowledge. Investors, partners, and scientists hear differently. And they’re all in the room. We develop strategy by finding the through-line that survives every audience. A positioning that holds. And clarifying what you might be sacrificing to get there.
Reframe the category. Not just your place in it.
Most biotechs position against competitors. We position to change how investors, partners, and collaborators see what’s possible. The kind of positioning that shapes conversations at conferences, survives due diligence, and scales with your pipeline.
The best names get rejected first.
Biotech naming carries weight others don’t. Scientific credibility, trademark complexity, cross-border clearance, URL scarcity. And naming by committee rarely survives contact with anything interesting. We push until the room is uncomfortable. That’s usually where the right name is hiding.
Going beyond the helix.
Investor decks. Scientific publications. Conference stands. Talent campaigns. Your visual identity has to work across all of them – without defaulting to the same molecule illustrations everyone else is using. Another molecule. Another helix. We design by removing what’s expected until what’s left is unmistakably yours.
Scientific precision. Human connection. Both.
Biotech messaging walks a tightrope. Too technical and you lose investors. Too simple and you lose credibility with KOLs. Most companies fall off in one direction and stay there. We develop tone of voice frameworks that translate complex science without diluting it. From pipeline narratives to partnership announcements to the slides your CEO presents at JPM.
Built to survive the real world.
Partner co-branding. Regulatory submissions. The scientist who joined after the rebrand. Your guidelines need to hold up when you’re not in the room to explain them. We build systems with enough structure for investor scrutiny and enough flexibility for the messy reality of a scaling biotech.